| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 19, 2004
Accepted on December 1, 2004
Clarita V. Odvina Center for Mineral Metabolism and Clinical Research and Division of Orthopedic Surgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8885; and Division of Bone and Mineral Metabolism, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202
* To whom correspondence should be addressed. E-mail: clarita.odvina{at}utsouthwestern.edu.
Alendronate, an inhibitor of bone resorption, is widely used in osteoporosis treatment. However, concerns have been raised about potential oversuppression of bone turnover during long-term use. We report on 9 patients who sustained spontaneous non-spinal fractures while on alendronate therapy, six of whom displayed either delayed or absent fracture healing for 3 months-2 yr during therapy.
Histomorphometric analysis of the cancellous bone showed markedly suppressed bone formation, with reduced or absent osteoblastic surface in most patients. Osteoclastic surface was low or low normal in 8 patients and eroded surface was decreased in 4. Matrix synthesis was markedly diminished with absence of double-tetracycline label and absent or reduced single-tetracycline label in all patients. The same trend was seen in the intracortical and endocortical surfaces.
Our findings raise the possibility that severe suppression of bone turnover may develop during long-term alendronate therapy, resulting in increased susceptibility to, and delayed healing of non-spinal fractures. Although co-adminstration of estrogen or glucocorticoids appears to be predisposing factors, this apparent complication can also occur with monotherapy. Our observations emphasize the need for increased awareness and monitoring for the potential development of excessive suppression of bone turnover during long-term alendronate therapy.
This article has been cited by other articles:
![]() |
E. B.K. Kwek, J. S.B. Koh, T. S. Howe, P. Lee, M. J. Seibel, B. A. Lenart, D. G. Lorich, and J. M. Lane More on Atypical Fractures of the Femoral Diaphysis N. Engl. J. Med., July 17, 2008; 359(3): 316 - 318. [Full Text] [PDF] |
||||
![]() |
L. Gehrig, J. Lane, and M. I. O'Connor Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons J. Bone Joint Surg. Am., June 1, 2008; 90(6): 1362 - 1374. [Full Text] [PDF] |
||||
![]() |
A. Brufsky, N. Bundred, R. Coleman, R. Lambert-Falls, R. Mena, P. Hadji, L. Jin, N. Schenk, S. Ericson, E. A. Perez, et al. Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole Oncologist, May 1, 2008; 13(5): 503 - 514. [Abstract] [Full Text] [PDF] |
||||
![]() |
Should We Be Concerned About Jaw Osteonecrosis with Oral Bisphosphonates? Journal Watch (General), April 8, 2008; 2008(408): 1 - 1. [Full Text] |
||||
![]() |
B. A. Lenart, D. G. Lorich, and J. M. Lane Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate N. Engl. J. Med., March 20, 2008; 358(12): 1304 - 1306. [Full Text] [PDF] |
||||
![]() |
E. J. MacLaughlin and C. L. Raehl ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults Am. J. Health Syst. Pharm., February 15, 2008; 65(4): 343 - 357. [Full Text] [PDF] |
||||
![]() |
I. R. Reid Pathogenesis of Osteonecrosis of the Jaw IBMS BoneKEy, February 1, 2008; 5(2): 69 - 77. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. G. RUSSELL, Z. XIA, J. E. DUNFORD, U. OPPERMANN, A. KWAASI, P. A. HULLEY, K. L. KAVANAGH, J. T. TRIFFITT, M. W. LUNDY, R. J. PHIPPS, et al. Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy Ann. N.Y. Acad. Sci., November 1, 2007; 1117(1): 209 - 257. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.L. Ruggiero and S.J. Drew Osteonecrosis of the Jaws and Bisphosphonate Therapy J. Dent. Res., November 1, 2007; 86(11): 1013 - 1021. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. McDonald, A. Schindeler, and D. G. Little Bisphosphonate Treatment and Fracture Repair IBMS BoneKEy, September 1, 2007; 4(9): 236 - 251. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Fujii, T. Hamano, S. Mikami, Y. Nagasawa, Y. Isaka, T. Moriyama, M. Horio, E. Imai, M. Hori, and T. Ito Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD) Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1601 - 1607. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Little, M. Ramachandran, and A. Schindeler The anabolic and catabolic responses in bone repair J Bone Joint Surg Br, April 1, 2007; 89-B(4): 425 - 433. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Bolland, A. B. Grey, A. M. Horne, S. E. Briggs, M. G. Thomas, R. B. Ellis-Pegler, A. F. Woodhouse, G. D. Gamble, and I. R. Reid Annual Zoledronate Increases Bone Density in Highly Active Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Men: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1283 - 1288. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Shoback Update in Osteoporosis and Metabolic Bone Disorders J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 747 - 753. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-K. Goh, K. Y. Yang, J. S. B. Koh, M. K. Wong, S. Y. Chua, D. T. C. Chua, and T. S. Howe Subtrochanteric insufficiency fractures in patients on alendronate therapy: A CAUTION J Bone Joint Surg Br, March 1, 2007; 89-B(3): 349 - 353. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. G. Russell Bisphosphonates: Mode of Action and Pharmacology Pediatrics, March 1, 2007; 119(Supplement_2): S150 - S162. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. McClung Bisphosphonate Therapy: To Stop or Not to Stop? IBMS BoneKEy, February 1, 2007; 4(2): 78 - 82. [Full Text] [PDF] |
||||
![]() |
S. L. Teitelbaum Osteoclasts: What Do They Do and How Do They Do It? Am. J. Pathol., February 1, 2007; 170(2): 427 - 435. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. B. Watts, S. T. Harris, M. R. McClung, J. P. Bilezikian, S. L. Greenspan, and M. M. Luckey Bisphosphonates and osteonecrosis of the jaw. Ann Intern Med, November 21, 2006; 145(10): 791 - 792. [Full Text] [PDF] |
||||
![]() |
R. Armamento-Villareal, N. Napoli, V. Panwar, and D. Novack Suppressed Bone Turnover during Alendronate Therapy for High-Turnover Osteoporosis N. Engl. J. Med., November 9, 2006; 355(19): 2048 - 2050. [Full Text] [PDF] |
||||
![]() |
American Dental Association Council on Scientific Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc, August 1, 2006; 137(8): 1144 - 1150. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Seeman and P. D. Delmas Bone quality--the material and structural basis of bone strength and fragility. N. Engl. J. Med., May 25, 2006; 354(21): 2250 - 2261. [Full Text] [PDF] |
||||
![]() |
S.-B. Woo, J. W. Hellstein, and J. R. Kalmar Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws Ann Intern Med, May 16, 2006; 144(10): 753 - 761. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Martin Current, New and Emerging Anti-Resorptive Drugs; Antibody Blockade Of RANKL Action IBMS BoneKEy, May 1, 2006; 3(5): 42 - 46. [Full Text] [PDF] |
||||
![]() |
A. J. Lasser MORE ABOUT BON J Am Dent Assoc, April 1, 2006; 137(4): 441 - 441. [Full Text] [PDF] |
||||
![]() |
R. G. G. RUSSELL Bisphosphonates: From Bench to Bedside Ann. N.Y. Acad. Sci., April 1, 2006; 1068(1): 367 - 401. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Michalska, J. J. Stepan, B. R. Basson, and I. Pavo The Effect of Raloxifene after Discontinuation of Long-Term Alendronate Treatment of Postmenopausal Osteoporosis J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 870 - 877. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. MIGLIORATI, J. CASIGLIA, J. EPSTEIN, P. L. JACOBSEN, M. A. SIEGEL, and S.-B. WOO Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper J Am Dent Assoc, December 1, 2005; 136(12): 1658 - 1668. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Valimaki and R. Tahtela Serum Tartrate-Resistant Acid Phosphatase 5b or Amino-Terminal Propeptide of Type I Procollagen for Monitoring Bisphosphonate Therapy in Postmenopausal Osteoporosis? Clin. Chem., December 1, 2005; 51(12): 2382 - 2385. [Full Text] [PDF] |
||||
![]() |
L.J. Deftos Treatment of Paget's Disease -- Taming the Wild Osteoclast N. Engl. J. Med., September 1, 2005; 353(9): 872 - 875. [Full Text] [PDF] |
||||
![]() |
Alendronate (Fosamax) and Risedronate (Actonel) Revisited Obstet. Gynecol., August 1, 2005; 106(2): 402 - 404. [Full Text] [PDF] |
||||
![]() |
B. G.M. Durie, M. Katz, J. Crowley, S.-B. Woo, K. Hande, P. G. Richardson, M. Maerevoet, C. Martin, L. Duck, P. Tarassoff, et al. Osteonecrosis of the Jaw and Bisphosphonates N. Engl. J. Med., July 7, 2005; 353(1): 99 - 102. [Full Text] [PDF] |
||||
![]() |
Minerva BMJ, June 11, 2005; 330(7504): E361 - E361. [Full Text] [PDF] |
||||
![]() |
Is Long-Term Bisphosphonate Therapy Safe? Journal Watch (General), April 5, 2005; 2005(405): 1 - 1. [Full Text] |
||||
![]() |
Minerva BMJ, April 2, 2005; 330(7494): 798 - 798. [Full Text] [PDF] |
||||
![]() |
S. L. Teitelbaum Osteoporosis and Integrins J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2466 - 2468. [Full Text] [PDF] |
||||
![]() |
E. Seeman and G. J. Strewler Clinical and Basic Research Papers - February 2005 Selections IBMS BoneKEy, March 1, 2005; 2(3): 1 - 5. [Full Text] [PDF] |
||||
![]() |
S. M. Ott Long-Term Safety of Bisphosphonates J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1897 - 1899. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |